Related Experiment Video
Updated: Feb 4, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer1, Jon Zugazagoitia2, Stephan Herbertz3
1H12O-CNIO Lung Cancer Clinical Research Unit Instituto de Investigación Hospital 12 de Octubre (i+12) & Centro Nacional de Investigaciones Oncológicas (CNIO), Av. De Córdoba SN, 28041 Madrid, Spain; CIBERONC, Spain.
Abstract:
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated with smoking. There are various sources of biological heterogeneity of KRAS-mutant NSCLC, including different genotypes that may be associated with specific clinical outcomes, the presence of other co-mutations that exhibit different biological features and drug sensitivity patterns, and mutant allelic content. The efficacy of chemotherapy in patients with KRAS-mutant NSCLC is generally poor and numerous novel therapeutic strategies have been developed. These approaches include targeting KRAS membrane associations, targeting downstream signalling pathways, the use of KRAS synthetic lethality, direct targeting of KRAS, and immunotherapy. Of these, immunotherapy may be one of the most promising treatment approaches for patients with KRAS-mutant NSCLC. Recent data also suggest the potential for distinct efficacy of immunotherapy according to the presence of other co-mutations. In view of the biological heterogeneity of KRAS-mutant NSCLC, treatment will likely need to be individualised and, in future, may require the use of rational combinations of treatment, many of which are currently under investigation.
Insights
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations drive non-small cell lung cancer (NSCLC). Immunotherapy shows promise for KRAS-mutant NSCLC, with tailored treatments and combinations being key for future patient care.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene driver mutation in Western non-small cell lung cancer (NSCLC) patients, often linked to smoking.
- KRAS-mutant NSCLC exhibits significant biological heterogeneity due to diverse genotypes, co-mutations, and varying mutant allelic content, impacting clinical outcomes and drug sensitivity.
- Traditional chemotherapy shows limited efficacy in KRAS-mutant NSCLC, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To review emerging therapeutic strategies for KRAS-mutant non-small cell lung cancer.
- To highlight the potential of immunotherapy as a promising treatment modality for this patient population.
- To emphasize the need for personalized treatment approaches considering the biological heterogeneity of KRAS-mutant NSCLC.
Main Methods:
- Review of current literature on KRAS-mutant NSCLC.
- Analysis of novel therapeutic strategies including direct KRAS targeting, pathway inhibition, synthetic lethality, and immunotherapy.
- Evaluation of the impact of co-mutations on immunotherapy efficacy.
Main Results:
- Several novel therapeutic strategies are under investigation for KRAS-mutant NSCLC.
- Immunotherapy is emerging as a particularly promising approach, with potential for varied efficacy based on co-mutational status.
- Biological heterogeneity necessitates individualized treatment plans.
Conclusions:
- KRAS-mutant NSCLC presents a complex biological landscape requiring tailored therapeutic interventions.
- Immunotherapy offers significant potential, especially when considering co-mutational profiles.
- Future treatment paradigms will likely involve rational combinations of therapies to address KRAS-mutant NSCLC heterogeneity.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:47Lung Capacity
01:57What is Conservation Biology?
00:59Gene Therapy
02:59Biological Effects of Radiation